|
| 產(chǎn)地 | 廣州 |
| 品牌 | Tanshtech |
| 貨號(hào) | N/A |
| 用途 | 科學(xué)研究 |
| 包裝規(guī)格 | 100mg |
| CAS編號(hào) | |
| 純度 | 95% |
| 是否進(jìn)口 | 否 |
【中文名稱】
腫liu淋巴管歸巢肽LyP-1修飾負(fù)載核酸/藥物的靶向脂質(zhì)體
【英文名稱】
Targeted liposome coated withLyP-1
【純 度】
95%以上
【保 存】
4℃保存
【規(guī) 格】
50mg，10mg/ml
【產(chǎn)品特性】
LyP-1 是一種環(huán)狀 9 個(gè)氨基酸的腫liu的定位肽，在多種腫liu相關(guān)細(xì)胞中，選擇性結(jié)合其 p32 receptor 蛋白。
LyP-1 (8?weeks) shows a remarkable reduction in plaque formation and plaque occupation rates in the LyP-1-treated group. In addition, a higher apoptotic rate in macrophages released from hypoxic plaques is observed after the treatment of LyP-1when compared to control peptide[1] .
The LyP-1 peptide is labeled with a near-infrared fluorophore (Cy5.5) for optical imaging.
At days 3, 7, 14 and 21 after inoculation with 4T1 cells, tumor-bearing BALB/C mice is injected Cy5.5-LyP-1 (0.8 nmol) through the middle phalanges of the upper extremities of the tumor-bearing mice. The fluorescence intensities were 0.024, 0.038, 0.048 and 0.106×106 photon/cm2/sec respectively at days 3, 7, 14 and 21 after tumor cell inoculation, which are 1.02, 1.63, 2.04, and 4.52-fold higher than in the contralateral LNs. Cy5.5-LyP-1 staining in LNs co-localized with LYVE-1, suggesting lymphatics-specific binding of LyP-1 peptide[1] .
LyP-1 Chemical Structure
CAS No. : 454487-07-1
系列產(chǎn)品（部分）
穿模肽TAT修飾負(fù)載核酸的靶向脂質(zhì)體
穿模肽R8修飾負(fù)載核酸的靶向脂質(zhì)體
靶向肽CRGD修飾負(fù)載核酸的靶向脂質(zhì)體
